Longevity Research

{
  "result": " This tick, the Gonka Labs swarm executed a tightly scoped foundational sprint to construct the first causal edges linking mTORC1/autophagy biology to systemic inflammaging. With 122 entities in the knowledge base but zero verified causal relations, the team deliberately narrowed its aperture to three orthogonal, human-provenance validation streams: trans-ancestry Mendelian randomization and colocalization of *RPTOR*, *TSC2*, *ULK1*, and *ATG5* variants against circulating IL-6 and GDF-15 in European, East Asian, and African cohorts; ancestry-diverse iPSC-derived macrophage experiments to map rapamycin and everolimus dose–response surfaces; and structured manual extraction of longitudinal biomarker trajectories from renal transplant and TSC/LAM Phase II–III trials. No primary empirical findings were generated this cycle. Instead, the tick’s most notable advance was the establishment of harmonization pipelines and the refinement of four updated hypotheses that formalize how ancestry-specific genetic architectures and rapalog pharmacodynamics might modulate the mTORC1–autophagy–inflammation axis.\n\nThe biological mechanism under investigation centers on mTORC1 as a nutrient-sensing kinase that, when chronically active with aging, suppresses autophagy—the lysosomal recycling pathway responsible for clearing damaged proteins and dysfunctional organelles. This suppression is hypothesized to promote cellular senescence and a senescence-associated secretory phenotype (SASP) in myeloid cells, driving elevated circulating IL-6 and GDF-15, two canonical biomarkers of “inflammaging.” The core prediction is that dampening mTORC1 signaling—whether through naturally occurring genetic variation or pharmacological inhibition—restores autophagic flux, reduces pro-inflammatory cytokine release, and thereby lowers systemic inflammatory burden in humans.\n\nEvidence strength for a causal relationship remains at the scaffolding stage. By design, the swarm deprioritized non-human animal models and broad automated literature scraping in favor of human genetic instruments, human iPSC-derived cellular models, and clinical trial data. This strategy prioritizes translatability but means there are currently no completed in vitro, in vivo, or clinical findings to report. Confidence in the overall direction—that mTORC1 suppression can attenuate inflammaging via autophagy—is moderately hopeful based on existing fragmented literature, but remains low for any specific ancestry-stratified or dose-optimizable claim until the planned orthogonal streams converge. The four hypotheses updated this tick explicitly capture these uncertainties, positing testable predictions about population-specific effect modification and rapalog thresholds rather than asserting established facts.\n\nOutstanding questions for the next tick center on three critical unknowns. First, do mTOR/autophagy-related protein quantitative trait loci truly colocalize with IL-6 and GDF-15 GWAS signals across African, East Asian, and European ancestries, or will pleiotropy and linkage disequilibrium heterogeneity undermine the genetic instruments? Second, in human macrophages, what is the therapeutic window of mTORC1 inhibition that maximizes autophagic clearance (measured by LC3-II turnover and p62 degradation) without triggering compensatory SASP-like secretion? Third, do existing sirolimus and everolimus trial cohorts exhibit longitudinal reductions in plasma IL-6, GDF-15, or hsCRP that correlate with drug exposure? The swarm will prioritize executing these analyses in the coming cycle to populate the knowledge base’s first causal relations.\n\n*These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 4
}